You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Details for New Drug Application (NDA): 220250


✉ Email this page to a colleague

« Back to Dashboard


NDA 220250 describes ELTROMBOPAG OLAMINE, which is a drug marketed by Annora Pharma, Amneal, Hetero Labs Ltd V, MSN, Somerset Theraps Llc, and Zydus Pharms, and is included in six NDAs. It is available from eight suppliers. Additional details are available on the ELTROMBOPAG OLAMINE profile page.

The generic ingredient in ELTROMBOPAG OLAMINE is eltrombopag olamine. There are three drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the eltrombopag olamine profile page.
Summary for 220250
Tradename:ELTROMBOPAG OLAMINE
Applicant:Msn
Ingredient:eltrombopag olamine
Patents:0
Pharmacology for NDA: 220250
Mechanism of ActionBreast Cancer Resistance Protein Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Thrombopoietin Receptor Agonists
UGT1A1 Inhibitors
UGT1A3 Inhibitors
UGT1A4 Inhibitors
UGT1A6 Inhibitors
UGT1A9 Inhibitors
UGT2B15 Inhibitors
UGT2B7 Inhibitors
Physiological EffectIncreased Megakaryocyte Maturation
Increased Platelet Production
Suppliers and Packaging for NDA: 220250
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 220250 ANDA Novadoz Pharmaceuticals LLC 72205-156 72205-156-30 30 TABLET, FILM COATED in 1 BOTTLE (72205-156-30)
ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 220250 ANDA Novadoz Pharmaceuticals LLC 72205-157 72205-157-30 30 TABLET, FILM COATED in 1 BOTTLE (72205-157-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 12.5MG ACID
Approval Date:Jan 14, 2026TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG ACID
Approval Date:Jan 14, 2026TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 50MG ACID
Approval Date:Jan 14, 2026TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links